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What’s new? 
• We evaluated the utility of clinical examination and non-invasive bedside tests in 
screening for peripheral artery disease in patients with diabetes. This study is unique 
in both the wide variety of tests investigated but also that all patients had ulceration. 
• Screening tests must reliably exclude the disease, as it is associated with both failure 
to heal and major amputation. According this criterion the only tests that would be 
considered suitable for screening are the toe brachial index and tibial waveform 
analysis. Simple bedside clinical examination such as pulse assessment are unreliable 
in excluding peripheral artery disease in this cohort. 
 
 
 
 
  
 
 
 
Abstract: 
Aims: 
Peripheral artery disease (PAD) is common in patients with diabetes related foot ulceration 
and is a risk factor for amputation. The best method for the detection or exclusion of PAD is 
unknown. This study investigated the utility of clinical examination and non-invasive bedside 
tests in screening for PAD in patients with diabetes related foot ulceration. 
Methods: 
60 patients presenting with new onset ulceration, to a hospital diabetes foot MDT, were 
studied. The accuracy of pulses, ankle pressure, toe pressure, toe brachial index (TBI), ankle 
brachial pressure index (ABPI), pole test at ankle, TcPO2 and distal tibial waveform on 
ultrasound was examined. The gold standard diagnostic test used was > 50% stenosis in any 
artery or monophasic flow distal to calcification in any ipsilateral vessel on Duplex 
ultrasound. 
Results: 
The negative (NLR) and positive (PLR) likelihood ratio of pedal pulse assessment (0.75, 
1.38) and the other clinical assessment tools was poor. Similarly, the NLR and PLR of ABPI 
(0.53, 1.69), TcPO2 (1.1, 0.81) and ankle pressure (0.67, 2.25) as screening tools was 
unsatisfactory. The lowest NLR was for tibial waveform assessment (0.15) and TBI (0.24). 
The highest PLRs were for toe pressure (17.58) and pole test at the ankle (10.29) but the 
NLRs were poor at 0.56 and 0.74 respectively. 
Conclusions: 
Pulse assessment and ABPI have limited utility in the detection of PAD in patients with 
diabetes foot ulceration. TBI and distal tibial waveforms are useful tools for selecting patients 
who may need further formal diagnostic testing. 
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Introduction: 
Diabetes mellitus affects large numbers of people globally. Worldwide there has been a 
dramatic increase in the prevalence, resulting in an inevitable rise in diabetes related 
complications and costs (1,2). It is estimated that foot complications associated with diabetes 
cost the National Health Service up to £662m annually in England and Wales (3). As diabetes 
becomes more prevalent, these costs are likely to increase. Diabetes mellitus is an important 
factor implicated in the development of both peripheral artery disease (PAD) and foot 
ulceration. In the general population with diabetes the prevalence of PAD is 10-26%, and in 
patients with associated foot ulceration this increases to over 50% (4-6). It is imperative to 
identify PAD, as it is associated with both delayed healing and amputation, so that 
appropriate interventions can be offered (7). 
Currently diabetes related foot ulcers are primarily managed by non-vascular specialists and a 
focussed clinical examination of the feet remains fundamental to patient assessment, 
particularly palpation of foot pulses (8,9). Nevertheless, palpation of foot pulses, especially in 
the presence of peripheral neuropathy, can be unreliable in screening for the presence of PAD 
in patients with diabetes (10). A range of non-invasive bedside screening tests are available 
as an adjunct to clinical examination, including ankle-brachial pressure index (ABPI), toe-
brachial pressure index (TBI), and transcutaneous pressure of oxygen (TcPO2) (8).  
Non-invasive screening tests for the detection of PAD among individuals with diabetes are 
considered important to estimate the risk of amputation, ulceration, wound healing and the 
presence of cardiovascular disease, yet there are no consensus recommendations to support 
one modality over another (11,12). Surprisingly, to date, the number of studies assessing the 
utility of PAD screening tests in patients with established ulceration has been limited in both 
number and scope (8). Most studies have either excluded or not separately reported the 
efficacy of PAD screening tools in patients with ulceration. Those studies that did detail 
assessment of patients with ulceration have only investigated a narrow range of tools. This is 
unfortunate as the identification of PAD in diabetes in the cohort with ulceration is more 
influential on management than those with intact feet. 
 
This study is the first to investigate the efficacy of both clinical assessment and a wide battery 
of PAD screening tools in patients with diabetes related foot ulceration.  
 
 
 
 
Participants and Methods:  
Ethical approval for the study was granted by the NHS Health Research Authority (NRES 
Committee London – City Road and Hampstead (Reference 12/LO/1579) and the research 
was performed according to the Declaration of Helsinki (2008). 
Study design and participants 
Patients with diabetes presenting to either a multidisciplinary diabetes foot clinic or 
emergency department with foot ulceration of less than 2 months duration were recruited into 
this prospective, single-centre observational study at a large teaching hospital.  
All patients with diabetes, regardless of type, presenting with primary lower limb ulceration 
were potentially eligible. The following patients were excluded: aged less than 18 years, 
previous revascularisation, non-diabetes related ulceration, patients lacking capacity to 
consent to inclusion in the study, and pregnant women. Informed, written consent was 
obtained from all patients who were willing to participate in the study. 
All study assessments were undertaken during the routine clinical visit of the patient. The 
management of the patient followed routine local protocols which are themselves compliant 
with national guidance (13). 
Clinical and Radiological Assessors 
Participants were clinically assessed, and the screening tests performed by a single post 
completion of training vascular surgical fellow, experienced in the management of diabetes 
related ulceration and familiar with the screening tools. Additional training was provided to 
the screener by the vascular laboratory for toe pressure and TcPO2 assessment to ensure 
compliance with manufacturer recommendation.  
The patient and their medical records were consulted for demographic data. 
Clinical examination included documentation of characteristics of the lower limbs, namely 
hair loss, muscle atrophy, dependent rubor, cool skin, blue or purple skin, capillary refill time 
and venous filling time. A capillary refill time of greater than 2 seconds and a venous filling 
time of over 15 seconds were classified as screen positive for peripheral artery disease. 
 
 
 
The presence of peripheral neuropathy was determined using a 10g monofilament (14). 
Peripheral pulses (femoral, popliteal, dorsalis pedis, and posterior tibial) were palpated 
bilaterally and classified as being either absent, weak, normal, or expansile. 
The ulcer was examined, and the severity was staged using the Site, Ischemia, Neuropathy, 
Bacterial infection, Area, Depth (SINBAD) classification (14,15). The Society of Vascular 
Surgery Wound Infection Ischaemia (SVS WIfI) score was used to classify the clinical status 
of the foot (16). 
Screening tests 
Screening tests were performed after a 20 minute rest period in a normal temperature (18-
20oC) room. Patients were placed in a 30o reclined position on a clinical examination couch. 
DUS examination was performed by a single experienced and accredited vascular 
sonographer. The investigator and sonographer were blinded to each other’s findings. 
Ankle pressure and ABPI’s 
The ankle and brachial pressures were measured using a manual inflatable cuff and a 
handheld continuous wave Doppler probe (Huntleigh Dopplex MD2, Huntleigh, UK). Ankle 
pressure of < 70 mmHg was considered abnormal. A resting ABPI was performed by using 
the brachial pressure on the right arm and the pressure values at the level of the posterior 
tibial artery and dorsalis pedis artery.  The highest calculated ABPI value was used for the 
analysis with a value of < 0.9 or > 1.3 classified as abnormal.  
Toe Pressures, TBI’s and TcPO2 
Toe pressures were measured using a laser Doppler probe and toe pressure cuff (Periflux 
5000 with PF 5010 Laser Doppler perfusion monitor unit and PF 5050 pressure unit with PF 
5051 pressure accessory kit, Perimed AB, Datavägen, Sweden) on the largest available toe. 
Three separate readings were obtained over a 5 minute interval and the mean of these values 
was used. Toe pressure of < 50 mmHg was considered abnormal. A TBI of ≤ 0.75 was 
considered abnormal. 
TcPO2 measurements were taken from the dorsum of the foot using (Periflux 5000 with PF 
5010 Laser Doppler perfusion monitor unit and PF 5020 temperature unit, Perimed AB, 
Datavägen, Sweden). The skin was cleaned with normal saline and then an adhesive ring 
applied and the manufacturer recommended contact liquid introduced. The probe was then 
 
 
 
attached and left in place for 15 minutes whilst the trace was recorded. TcPO2 < 30 mmHg 
was considered abnormal (17). 
Pole test 
The pole test was performed using a handheld Doppler probe (Huntleigh Dopplex MD2, 
Huntleigh, UK). With the patient supine the leg was elevated passively at the hip whilst 
continuing to listen for the Doppler signal. The height in centimetres at which the Doppler 
signal was lost was recorded. To confirm flow was lost, the leg was lowered and considered 
positive if the flow to the vessel returned. The test was repeated on both the dorsalis pedis 
and posterior tibial arteries bilaterally. The highest of the two measurements was used for 
analysis. If there was no loss of flow this was recorded or if the patient was unable to elevate 
the leg this was recorded (18,19). 
Waveform analysis 
Waveforms recorded at the level of the distal tibial arteries were included in the analysis to 
verify whether Doppler waveforms at this level could be discriminatory in identifying 
peripheral artery disease. Recordings were made at the level of the medial malleolus, the 
dorsalis pedis and in the mid-calf for the peroneal artery. It is important to note that this part 
of the analysis was not blinded i.e. the vascular sonographer performing the reference scan 
also performed the tibial waveform analysis. 
Gold standard test 
Duplex ultrasound scan (DUS) was performed by an accredited vascular scientist using a GE 
Logic E9 ultrasound scanner (GE, Wisconsin, USA). The abdominal, femoral and lower limb 
arteries (femoral, popliteal and tibial) supplying the ulcerated limb were studied. A C5-1MHz 
curvilinear array was used to assess the abdominal vessels while a linear 3-9 MHz transducer 
was used for the lower limb arteries. All the arteries were examined by using a combination 
of B-mode imaging, colour Doppler and Spectral Doppler ultrasound in transverse and 
longitudinal planes. Peak systolic velocity (PSV) were measured throughout the iliac, 
femoral, popliteal and tibial arteries and were recorded for further analysis only in the distal 
tibial arteries. PSV was measured at the point in the vessel where the highest velocity was 
detected.  The PSV ratio between a stenosed region and the proximal PSV were used to grade 
stenosis and were classified as abnormal when the PSV ratio was > 2, which represents a 
stenosis of > 50%. 
 
 
 
Flow velocity waveforms were also recorded. Triphasic or biphasic waveforms with fast 
systolic rise time and no flow at end-diastole were considered normal lower limb resting 
waveforms. Monophasic (damped) waveforms were considered abnormal and indicative of 
proximal arterial obstructive disease. At the site of a stenosis the flow waveform has 
abnormally high velocities throughout the cardiac cycle with a ragged outline due to the 
presence of turbulent flow. Distal to a stenosis the waveform is damped with a prolonged 
systolic rise time and forward flow throughout the cardiac cycle.  
PAD was defined as > 50% stenosis in any named lower limb artery or monophasic flow 
beneath a calcified segment (13,20,21). 
Statistical Analysis 
Statistical analysis was performed using R 3.1.1 (R Core Team, R Foundation for Statistical 
Computing, Vienna, Austria).  
The negative likelihood ratio (NLR) was the primary outcome of interest. The positive 
likelihood ratio (PLR), sensitivity, specificity, positive and negative predictive values are also 
reported. The NLR is the ratio of the probability of testing negative in an individual without 
versus with the disease.  The PLR is the ratio of the probability of testing positive in an 
individual with versus without the disease.  
 
Results 
Some 60 limbs in 60 patients with diabetes related foot ulceration were included in the study 
(Table 1). The ulcer characteristics of the study patients are detailed in table 2 and 3. A total 
of 20 (33%) of the patients had PAD on DUS. 
The NLR and PLR of pedal pulse assessment (NLR 0.75, PLR 1.38) and the other physical 
examination findings was poor (Table 4). Similarly the NLR and PLR of ABPI (0.53, 1.69), 
TcPO2 (1.1, 0.81) and ankle pressure (0.67, 2.25) as screening tools to identify PAD was 
unsatisfactory. The lowest NLR was for tibial waveform assessment (0.15) and toe brachial 
pressure index (0.24). The highest PLRs were for toe pressure (17.58) and pole test at the 
ankle (10.29) but the NLRs were again poor at 0.56 and 0.74 respectively (Table 4).  
 
 
 
 
Discussion 
The identification of PAD is crucial to the management of diabetes related foot ulceration as 
it risk stratifies patients that are at greater risk of failure to heal, amputation and, perhaps 
more importantly, those who may potentially benefit from revascularisation (7). The most 
important characteristic of a screening tool in patients with established ulceration is therefore 
the ability to exclude PAD. Any screen positive patient will need to undergo one or more 
reference investigation to confirm or exclude PAD as well as detail the anatomy of the lower 
limb arterial tree. The consequences of a false negative are potentially more severe, than a 
false positive, as the initial diagnostic tests utilised by most units are non-invasive and 
unlikely to lead to harm. To this end a negative likelihood ratio of less than 0.1 provides 
convincing screening evidence that the disease is absent (22). In our study no test achieved 
this cut off but the toe brachial pressure index and tibial waveform analysis were close 
enough that they can be recommended as screening tools. We would recommend that 
clinicians without access to these tools request formal imaging to exclude PAD. 
Unfortunately, the commonly used clinical assessments including pulse assessment and 
screening tests such as ankle pressure and ABPI are not very useful for disease exclusion in 
patients with established ulceration. 
This analysis is consistent with previous research that has demonstrated that the utility of 
pulse assessment, ankle pressure and ABPI to identify PAD in patients with neuropathy (85% 
of our cohort) is low. It is anticipated that the utility of these tests diminishes further in 
patients with ulceration. This is expected as oedema, calcification and arteriovenous shunting 
all increase with progression of diabetes and unduly influence the outcome of these screening 
tests (23). Previous studies assessing the utility of ABPI in patients with intact feet have 
demonstrated NLRs from < 0.1 to 0.5 (25,26). Although Aboyans et al. reported a NLR of 
<0.1 in a cohort with 94% ulceration most other studies which explicitly include some 
patients with ulcers report NLRs ranging from 0.3 to 0.7 (20, 26-28). Williams et al. reported 
that the NLR for TBI was <0.1 for patients with intact feet and neuropathy (24). Predictably 
in our cohort with ulceration TBI performed less well with an NLR of 0.24. Nevertheless toe 
brachial index probably represents the most useful screening tool for PAD in the community 
foot clinic where access to diagnostic tests may be limited.  Unfortunately, due to previous 
minor amputations or digital ulcers not all patients can undergo this investigation. 
 
 
 
Waveform analysis was the best screening tool to exclude PAD in our study and Normahani 
and colleagues demonstrate that it is possible to train podiatrists to perform a focused Duplex 
ultrasound scan of the tibial vessels at the ankle (29). The costs of training and availability of 
ultrasound machines may be a limitation. There are medical devices available that can record 
the ankle pulse waveform but their utility in patients with established ulceration remains to be 
assessed (30). We did not have access to this technology at the time of the study. An 
alternative is to refer all patients with ulceration for a limited tibial waveform scan by a 
vascular sonographer. Only those who screen positive could then proceed to full Duplex 
ultrasound 
Strengths and Limitations 
This study focused on the identification of PAD as the primary outcome of interest. Despite 
the importance of PAD, not all patients with PAD require revascularisation to heal their ulcer. 
The additional consideration is whether perfusion is adequate to heal the ulcer with best 
medical and wound care i.e. is revascularisation required. This is a more complex and 
different question and would require a different study design to reach a conclusion. Screening 
tools that exclude PAD can help to identify patients that do not warrant ongoing referral to an 
MDT that includes a vascular specialist who can clinically address this question by assessing 
the severity of artery disease, ulcer characteristics and presence of infection. 
We chose a definition of abnormal ABPI < 0.9 or > 1.3. Most studies assessing ABPIs utility 
as a screening test for PAD use < 0.9. Our reason was once again that we were restricting our 
paper to those with established ulceration were robust exclusion is more important than 
specificity. 
To our knowledge this is the first paper that tests such a wide variety of PAD screening tools 
in patients with ulceration. Other screening tools are available that were not included in this 
study such as pulse oximetry. 
The clinical assessment of our patients was performed by a post completion of training 
vascular fellow. The applicability of this assessment to non-specialist nurse or podiatrists is 
unknown. We would anticipate that the ability of pulse assessment to exclude PAD would be 
even worse if undertaken by non-specialists. 
 
 
 
 
Conclusions 
Toe brachial index and tibial waveform analysis at the ankle are viable screening tools to 
exclude PAD in patients with foot ulceration where the equipment and training for their 
utilisation exists or can be set up. Traditionally used clinical assessment and alternative 
screening tools perform poorly in excluding PAD in patients with established diabetes related 
foot ulceration. In the absence of appropriate TBI or tibial waveform analysis all patients 
with diabetes related foot ulceration should undergo diagnostic vascular imaging unless there 
is a very rapid response to best medical and wound care. 
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Tables 
 
Age 66 years (range 29-92) 
Male 45 (75%)  
Inpatient 15 (25%) 
Duration of diabetes 2 years (range 0.04-62) 
HbA1c 65 mmol/mol (range 36-106) 
Diabetes:  
Type I 7 (12%) 
Type II:  
Diet/Oral hypoglycaemic 23 (28%) 
Insulin 30 (50%) 
Smoking:  
Never or stopped > 10 years 44 (73%) 
Stopped < 10 years ago 9 (15%) 
Abstinence < 1 year or < 1 pack/day 3 (5%) 
> 1 pack/day 4 (7%) 
Hypertension 44 (73%) 
Hyperlipidaemia:  
No 10 (17%) 
Diet controlled 7 (12%) 
Diet and drug therapy 43 (72%) 
Previous TIA or stroke 4 (7%) 
Cardiac disease 16 (27%) 
Chronic kidney disease 23 (38%) 
Pulmonary disease 6 (10%) 
Table 1 Demographics of study patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SINBAD No. 
Site 20 (33%) 
Ischaemia 35 (58%) 
Neuropathy 51 (85%) 
Infection 19 (32%) 
Area 25 (58%) 
Depth 13 (22%) 
Total score:  
0 3 (5%) 
1 7 (12%) 
2 22 (37%) 
3 8 (13%) 
4 7 (12%) 
5 10 (17%) 
6 3 (5%) 
Table 2 SINBAD ulcer classification of study patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SVS WIfI No.  
Wound:   
0 0 
1 44 (73%) 
2 8 (13%) 
3 8 (13%) 
Ischaemia:  
0 62 (37%) 
1 23 (14%) 
2 12 (7%) 
3 3 (2%) 
Infection:  
0 36 (60%) 
1 10 (17%) 
2 8 (13%) 
3 6 (10%) 
Table 3 SVS WIfI ulcer classification of study patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Sensitivity Specificity 
Positive predictive 
value 
Negative predictive 
value 
Positive likelihood 
ratio 
Negative likelihood 
ratio 
Either pedal pulse 0.55 0.60 0.41 0.73 1.38 0.75 
Hair loss 0.8 0.4359 0.4211 0.8095 1.42 0.46 
Atrophy 0.5 0.8718 0.6667 0.7727 3.90 0.57 
Dependent rubor 0 1 Not discriminatory* 0.661 Not discriminatory* 1.00 
Cool skin 0.3 0.8974 0.6 0.7143 2.92 0.78 
Blue/purple skin 0 0.9211 0 0.6364 0 1.09 
Capillary refill 0.4211 0.6316 0.3636 0.6857 1.14 0.92 
Venous filling 0 1 Not discriminatory† 0.6512 Not discriminatory† 1.00 
       
       
Ankle pressure 0.47 0.79 0.53 0.75 2.25 0.67 
Toe pressure 0.45 0.97 0.90 0.78 17.58 0.56 
Toe brachial pressure index  0.89 0.45 0.45 0.89 1.62 0.24 
Ankle brachial pressure index 0.68 0.59 0.46 0.79 1.69 0.53 
Pole test at ankle 0.28 0.97 0.83 0.73 10.29 0.74 
TcPO2 0.28 0.66 0.28 0.66 0.81 1.10 
Waveform analysis 0.85 1.00‡ 1.00 ‡ 0.93 Diagnoses PAD‡ 0.15 
Table 4 Diagnostic utility of physical examination of and screening tests to identify peripheral artery disease compared to Duplex ultrasound scan 
 
*Not discriminatory because dependent rubor was not elicited in any patient. 
† Not discriminatory because impairment of venous filling was not elicited in any patient. 
‡ The gold standard definition of PAD used included monophasic (damped) waveforms in any vessel, therefore the specificity and positive predictive value 
ratios are 1 and, positive likelihood is effectively infinite and diagnoses PAD. 
 
 
 
 
 
 
 
 
